Basic Information
| LncRNA/CircRNA Name | circ_0001427 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | enzalutamide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR |
| Sample | PCa cell line(EnzS-C4-2) |
| Expression Pattern | down-regulated |
| Function Description | Here we found from human clinical sample survey that circRNA17 (hsa_circ_0001427) has a lower expression in higher Gleason score PCa, and results from in vitro cell lines studies also revealed the lower expression in CRPC C4-2 Enz-resistant (EnzR-C4-2) cells compared to their parental Enz-sensitive (EnzS-C4-2) cells. |
| Pubmed ID | 30674872 |
| Year | 2019 |
| Title | Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. |
External Links
| Links for circ_0001427 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |